Tavros Therapeutics Inc. and Vividion Therapeutics Inc., a subsidiary of Bayer AG, have entered into a collaboration agreement to discover or target four oncology targets across an initial 5-year term.
Suzhou Zion Pharma Technology Co. Ltd. has divulged serine-protein kinase ATM (ataxia telangiectasia mutated) inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has presented furan fused ring-substituted glutarimides as proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to androgen receptor-targeting moiety reported to be useful for the treatment of prostate cancer.
Shenzhen Forward Pharmaceutical Co. Ltd. has divulged estrogen receptor α (ERα) antagonists and/or degradation inducers reported to be useful for the treatment of cancer.
Topoisomerase I (topo I) and cyclooxygenase-2 (COX-2) are known targets in colon cancer, and Chinese scientists have sought dual topo I/COX-2 inhibitors to provide anticancer activity without the potential for side effects seen with combined therapy.
Maze Therapeutics has presented glycogen [starch] synthase, muscle (GYS1) inhibitors reported to be useful for the treatment of cancer and Pompe disease.
Innovotex Inc. has acquired an exclusive and perpetual license, facilitated by the Discovery to Impact group at the University of Texas at Austin, to an innovative discovery platform and corresponding patent portfolio to identify and design therapeutic candidates for a range of solid tumor indications.
Targeting tyrosine-protein kinase Lck (LCK) with dasatinib has demonstrated activity against T-cell acute lymphoblastic leukemia (T-ALL). To make the effects more lasting, researchers from St. Jude Children's Research Hospital and the University of Pennsylvania designed proteolysis targeting chimeras (PROTACs) using dasatinib as an LCK ligand and phenyl-glutarimide as a cereblon-directing moiety.
RSS
